tbuckley/cabot-search huggingface dataset:
Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer
Authors: Robert C. Grant, Rahim Moineddin, Zhan Yao, Melanie Powis, Vishal Kukreti, Monika K. Krzyzanowska
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Emergency department visits and hospitalizations after starting systemic therapy for cancer are frequent, undesirable, and costly. A score to quantify the risk of needing acute care can inform decision-making and facilitate the development of preventive interventions. <h3>Objective</h3> To develop and validate a score to predict early use of acute care after initiating systemic therapy for cancer. <h3>Design, Setting, and Participants</h3> A retrospective population-based cohort study was conducted between July 1, 2014, and June 30, 2015. Patients with cancer were eligible if they started a new systemic therapy for cancer, regardless of line of therapy. A total of 12 162 patients in Southwestern Ontario, Canada, formed the development cohort and 15 845 patients in Northeastern Ontario formed the validation cohort. Data analysis was conducted from December 1, 2016, to August 10, 2019. <h3>Exposures</h3> The Prediction of Acute Care Use During Cancer Treatment (PROACCT) score was created based on logistic regression in the development cohort. Combinations of cancer type and regimens were grouped into quintiles based on risk of needing acute care. The score was assessed in the validation cohort. <h3>Main Outcomes and Measures</h3> At least 1 emergency department visit or hospitalization within 30 days after starting systemic therapy for cancer identified from administrative databases. <h3>Results</h3> Among the 12 162 patients in the development cohort, 6903 were women and 5259 were men (mean [SD] age, 62.9 [12.6] years); among the 15 845 patients in the validation cohort, 9025 were women and 6820 were men (mean [SD] age, 62.9 [12.6] years). Use of acute care occurred within 30 days after initiation of systemic therapy in 3039 patients (25.0%) in the development cohort and 4212 patients (26.6%) in the validation cohort. Three characteristics predicted early use of acute care and formed the PROACCT score: combination of cancer type and treatment regimen, age, and emergency department visits in the prior year (C statistic, 0.67; 95% CI, 0.66-0.69;<i>P</i> &lt; .001). Other characteristics including patient-reported symptoms did not improve performance. In the validation cohort, the PROACCT score was associated with use of acute care (odds ratio per point increase, 1.22; 95% CI, 1.20-1.24;<i>P</i> &lt; .001), had a C statistic of 0.61 (95% CI, 0.60-0.62;<i>P</i> &lt; .001), was reasonably calibrated, and provided net benefit in decision curve analysis. <h3>Conclusions and Relevance</h3> The PROACCT score predicted the risk of early use of acute care in patients starting systemic treatment for cancer and could be incorporated at the point of care to select patients for preventive interventions. Future studies should validate the PROACCT score in other settings.
Fine-Scale Haplotype Structure Reveals Strong Signatures of Positive Selection in a Recombining Bacterial Pathogen
Authors: Brian Arnold, Mashaal Sohail, Crista Wadsworth, Jukka Corander, William P Hanage, Shamil Sunyaev, Yonatan H Grad
Journal: Molecular Biology and Evolution (2019)

Abstract Identifying genetic variation in bacteria that has been shaped by ecological differences remains an important challenge. For recombining bacteria, the sign and strength of linkage provide a unique lens into ongoing selection. We show that derived alleles &amp;lt;300 bp apart in Neisseria gonorrhoeae exhibit more coupling linkage than repulsion linkage, a pattern that cannot be explained by limited recombination or neutrality as these couplings are significantly stronger for nonsynonymous alleles than synonymous alleles. This general pattern is driven by a small fraction of highly diverse genes, many of which exhibit evidence of interspecies horizontal gene transfer and an excess of intermediate frequency alleles. Extensive simulations show that two distinct forms of positive selection can create these patterns of genetic variation: directional selection on horizontally transferred alleles or balancing selection that maintains distinct haplotypes in the presence of recombination. Our results establish a framework for identifying patterns of selection in fine-scale haplotype structure that indicate specific ecological processes in species that recombine with distantly related lineages or possess coexisting adaptive haplotypes.
Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens
Authors: Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Marina Iakovaki, Charis Matsouka, Despina Mparmparousi, Nikitas Nikitas, Dimitra Gika, Irene Grapsa, Erasmia Psimenou, Evangelos Terpos
Journal: Blood (2010)
REFUGE Challenge: A unified framework for evaluating automated methods for glaucoma assessment from fundus photographs
Authors: José Ignacio Orlando, Huazhu Fu, João Barbosa Breda, Karel van Keer, Deepti R. Bathula, Andrés Diaz-Pinto, Ruogu Fang, Pheng-Ann Heng, Jeyoung Kim, JoonHo Lee, Joonseok Lee, Xiaoxiao Li, Peng Liu, Shuai Lu, Balamurali Murugesan, Valery Naranjo, Sai Samarth R. Phaye, Sharath M. Shankaranarayana, Apoorva Sikka, Jaemin Son, Anton van den Hengel, Shujun Wang, Junyan Wu, Zifeng Wu, Guanghui Xu, Yongli Xu, Pengshuai Yin, Fei Li, Xiulan Zhang, Yanwu Xu, Hrvoje Bogunović
Journal: Medical Image Analysis (2019)
Proteasome Inhibitors and a Fusicoccin Derivative (ISIR-042) Cooperatively Inhibit Proliferation of Myeloma Cells through Induction of C/EBP-Homologous Protein (CHOP/GADD153)
Authors: Takaaki Miyake, Yoshio Honma, Tsutomu Takahashi, Koshi Kawakami, Takahiro Okada, Satoshi Kumanomido, Fumiyoshi Ikejiri, Yumi Jo, Chie Onishi, Ichiro Moriyama, Inoue Masaya, Ritsuro Suzuki, Junji Suzumiya
Journal: Blood (2016)
Identification and Characterization of Peptide Ligands for Stereotyped Subset and Non-Subset B-Cell Receptors of Patients with M- and U-CLL.
Authors: Manuela Woelfle, Till Seiler, Rosa Catera, Hartmut Dohner, Stephan Stilgenbauer, Steven L Allen, Kanti R Rai, Charles Chu, Nicholas Chiorazzi
Journal: Blood (2009)
Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience
Authors: Morag Griffin, Austin Kulasekararaj, Shreyans Gandhi, Peter Hillmen, Talha Munir, Stephen John Richards, Louise Arnold, Kathryn Riley, Katherine Pelton, Nana Benson-Quarm, Isabel Duggins, Judith C. W. Marsh, Anita Hill
Journal: Blood (2016)
Varialibility of Neurological Complications in the Treatment of Acute Lymphoblastic Leukemia:Experience of a Single Pediatric Institution
Authors: Rosanna Parasole, Fara Petruzziello, Nicoletta Marra, Luciano Marchese, Argia Mangione, Ernesto Cianciulli, Giuseppe Menna, Aldo Misuraca, Vincenzo Poggi
Journal: Blood (2008)
Risk-Group Stratified and Minimal Residual Disease (MRD)-Guided Treatment with Extended ATRA and Reduced-Anthracycline Chemotherapy in Childhood Acute Promyelocytic Leukemia (APL): Results from ICC APL Study 01 (NCT01226303; EudraCT 2008-002311-40)
Authors: Anna Maria Testi, Andrea Pession, David Grimwade, Daniela Diverio, Christine Ragu, Sarah Elitzur, Alcira Fynn, Henrik Hasle, Jutte Van der Werff ten Bosch, Owen Smith, Brenda Gibson, Franco Locatelli, Gertjan J.L. Kaspers
Journal: Blood (2015)
Ex Vivo Large Scale Generation of Human Platelets from Cord Blood CD34+ Cells.
Authors: Takuya Matsunaga, Ikuta Tanaka, Masayoshi Kobune, Yutaka Kawano, Maki Tanaka, Takehide Akiyama, Kageaki Kuribayashi, Takafumi Ninomiya, Hirofumi Hamada, Yoshiro Niitsu
Journal: Blood (2005)
Comprehensive Genetic Analysis in Cases of Juvenile Myelomonocytic Leukemia for Prognostic Estimation
Authors: Norihiro Murakami, Hideki Muramatsu, Yusuke Okuno, Hirotoshi Sakaguchi, Kenichi Yoshida, Toshihide Ueno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Daiei Kojima, Yuko Sekiya, Kyogo Suzuki, Nozomu Kawashima, Atsushi Narita, Nobuhiro Nishio, Asahito Hama, Satoru Miyano, Seishi Ogawa, Hiroyuki Mano, Seiji Kojima, Yoshiyuki Takahashi
Journal: Blood (2016)
Curcumin Decreases Cytokine Levels Involved in Mucositis in Autologous Transplant Setting: A Pharmacokinetic-Pharmacodynamic Study.
Authors: Navin Khattry, Jayant Gawande, Pravin Patil, Bhausaheb Bagal, Sadhna Kannan, Shubha Chiplunkar, Vikram Gota
Journal: Blood (2012)
Junctional Adhesion Molecule 2 Represents a Novel Subset of Hematopoietic Stem Cells Poised for T Lymphopoiesis
Authors: Visnja Radulovic, Mark van der Garde, Valgardur Sigurdsson, Alya Zriwil, Svetlana Soboleva, Shin Kaneko, Ewa Sitnicka Quinn, Kenichi Miharada
Journal: Blood (2016)
Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial
Authors: Matthew M Heeney, Brigitta U. Mueller, Brad Baltz, Patricia Adams-Graves, Elizabeth Yang, Carole Paley, Jason Esposito MSHS, McNamara Katie MSHS CCRA, Elliott Vichinsky
Journal: Blood (2013)
Prediction of Response to Recombinant Erythropoietin Plus Granulocyte-Colony Stimulating Factor Following a Single Subcutaneous Bolus in Patients with Myelodysplastic Syndromes; a Randomised Placebo Controlled Study.
Authors: David Bowen, Ann Hyslop, Norene Keenan, Michael Groves, Dominic Culligan, Peter Johnson, Ann Shaw, Fiona Geddes, Patricia Evans, John Porter, Ivor Cavill
Journal: Blood (2004)
Prevalence, risk factors and genetic characterisation of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae (ESBL-E and CPE): a community-based cross-sectional study, the Netherlands, 2014 to 2016
Authors: Gerrita van den Bunt, Wilfrid van Pelt, Laura Hidalgo, Jelle Scharringa, Sabine C. de Greeff, Anita C. Schürch, Lapo Mughini-Gras, Marc J.M. Bonten, Ad C. Fluit
Journal: Eurosurveillance (2019)

BackgroundThe epidemiology of carriage of extended-spectrum beta-lactamase-producing (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE) in the general population is unknown.AimIn this observational study, the prevalence and risk factors for intestinal ESBL-E and CPE carriage in the Dutch general population were determined. ESBL-E were characterised.MethodsFrom 2014 to 2016, ca 2,000 residents were invited monthly to complete a questionnaire and provide a faecal sample, which was tested for ESBL-E. The first 1,758 samples were also tested for CPE. Risk factors for ESBL-E carriage were identified by multivariable logistic regression analysis. ESBL-E isolates underwent whole genome sequencing.ResultsOf 47,957 individuals invited, 4,177 (8.7%) completed the questionnaire and provided a faecal sample. ESBL-E were detected in 186 (4.5%) individuals, resulting in an adjusted prevalence of 5.0% (95% confidence interval (CI):3.4-6.6%). Risk factors were: born outside the Netherlands (odds ratio (OR): 1.99; 95% CI: 1.16-4.54), eating in restaurants > 20 times/year (OR: 1.70; 95% CI: 1.04-2.76), antibiotic use < 6 months ago (OR: 2.05; 95% CI: 1.05-4.03), swimming in sea/ocean < 12 months ago (OR: 1.63; 95% CI: 1.11-2.39), travelling to Africa (OR: 3.03; 95% CI: 1.23-7.46) or Asia (OR: 2.00; 95% CI: 1.02-3.90) < 12 months ago, and not changing kitchen towels daily (OR: 2.19; 95% CI: 1.24-3.87). The last had the largest population attributable risk (PAR) (47.5%). Eighty-four of 189 (44.4%) ESBL-E isolates carried blaCTX-M-15. Escherichia coli isolates belonged to 70 different sequence types (ST)s, of which ST131 (42/178 isolates; 23.6%) was most prevalent. Associations were observed between IncFIA plasmids and ST131 and blaCTX-M-27, and between IncI1 and ST88 and blaCTX-M-1. No CPE were detected.ConclusionsThe prevalence of ESBL-E carriage in the Netherlands' community-dwelling population is 5.0%. Identified risk factors were mostly travelling (particularly to Asia and Africa) and kitchen hygiene. CPE were not detected.
Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.
Authors: Richard A. Larson, Yen Lin Chia, Camille Granvil, François Guilhot, Brian J. Druker, Stephen G O'Brien, MD, Michele Baccarani, Timothy P. Hughes, Jerry R. Nedelman, Yanfeng Wang
Journal: Blood (2009)
Low Level Residual Extravascular Haemolysis Is Commom Following Eculizumab Treatment In Paroxysmal Nocturnal Haemoglobinuria(PNH), but Does Not Affect Transfusion Requirement
Authors: Austin G Kulasekararaj, Dupe Odunsi, Pramila Krishnamurthy, Hayden Janet, Ibrahim Momoh, Ghulam J. Mufti, Judith C. W. Marsh, Modupe Elebute
Journal: Blood (2010)
Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer
Authors: Hidetaka Tsumura, Chigusa Morizane, Shogo Nomura, Hideaki Takahashi, Naohiro Okano, Nobumasa Mizuno, Hironaga Satake, Kunihiro Tsuji, Kazuhiko Shioji, Akinori Asagi, Kohichiroh Yasui, Hiroyuki Miyakawa, Atsushi Ishiguro, Takashi Ogura, Makoto Ueno, Kazutoshi Tobimatsu, Takeshi Terashima, Masafumi Ikeda, Takuji Okusaka, Junji Furuse
Journal: Annals of Oncology (2019)
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML
Authors: Federico Quaini, Rodanthi Fioretzaki, Monica Crugnola, Angela Falco, Denise Madeddu, Luisa Craviotto, Benedetta Cambò, Lucia Prezioso, Gabriella Sammarelli, Giannalisa Todaro, Gallia Graiani, Cristina Mancini, Eugenia Martella, Francesca Re, Nicola Giuliani, Franco Aversa
Journal: Blood (2016)
Transplant-Associated Thrombotic Microangiopathy: Prevalence, Prognostic Factors and Treatment Outcomes in Unrelated Allogeneic Transplant for Hematologic Diseases
Authors: Ioanna Sakellari, Ioannis Batsis, Zoi Boussiouu, Despina Mallouri, Varnavas Konstantinou, Michail Iskas, Anna Vardi, Stergios Papadimitriou, Alkistis Panteliadou, Christos Smias, Evangelia Yannaki, Asimina Fylaktou, Aliki Tsompanakou, Chrysanthi Vadikoliou, Panayotis Kaloyannidis, Taisir Natse, Gerasimos Bamichas, Eleni Gavriilaki, Achilles Anagnostopoulos
Journal: Blood (2016)
Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial
Authors: Paola Neri, Ranjan Maity, Jonathan J Keats, Ines Tagoug, Justin Simms, Daniel Auclair, Sagar Lonial, Nizar J. Bahlis
Journal: Blood (2016)
Comparative Transcriptome Analyses of Laser-Captured Human Primary Megakaryocytes with Platelets from the Same Healthy Donors and from Cord Blood Derived Megakaryocytes
Authors: Seema Bhatlekar, Srikanth Nagalla, Cory Lindsey, Renata Pellegrino, Lin Ma, Xianguo Kong, Leonard C. Edelstein, Paul F. Bray
Journal: Blood (2016)
Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
Authors: Shaji Kumar, William I Bensinger, Craig B. Reeder, Todd M. Zimmerman, James R. Berenson, Deborah Berg, Guohui Liu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Ruben Niesvizky
Journal: Blood (2011)
Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors
Authors: Felicia Gomez, Matthew Matlock, Kilannin Krysiak, Yi-Shan Lee, Eric J. Duncavage, Michelle O'Laughlin, Malachi Griffith, Todd A Fehniger, Lukas D. Wartman, Obi L. Griffith
Journal: Blood (2016)
MAGE-C1/CT7 Inhibition Increases Myeloma Cell Line Sensitivity to Bortezomib-Induced Apoptosis: New Target for Myeloma Therapy?
Authors: Fabricio de Carvalho, Erico T. Costa, Anamaria A. Camargo, Juliana C. Gregorio, Cibele Masotti, Valeria C.C. Andrade, Bryan E. Strauss, Otavia L. Caballero, Djordje Atanackovic, Gisele W.B. Colleoni
Journal: Blood (2010)
Immunoglobulin/T-Cell Receptor (Ig/TCR) Allele Usage in Normal and on Treatment Bone Marrow Samples in Childhood Acute Lymphoblastic Leukaemia - Implications for NGS Based MRD Analysis
Authors: John Moppett, Stephanie Wakeman, Marc Duez, Jack Bartram, Gary Wright, Mike Hubank, Helen Williamson, Paul Archer, Jerry Hancock
Journal: Blood (2016)
The Expression of Bcl-6 In Diffuse Large B Cell Lymphoma (DLBCL) Is Associated with Improved Progression Free Survival and Overall Survival Following Front-Line Rituximab-Chemotherapy
Authors: Pooja Advani, Nuttapong Ngamphaiboon, Sulada Pukiat, Julio Chavez, George Deeb, Anjana Elefante, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2010)
Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study
Authors: Franco Locatelli, Myriam Labopin, Gerard Michel, Rupert Handgretinger, Cristina Diaz de Heredia, Alice Bertaina, Ayas Mouhab, Tracey O'Brien, Jacqueline M Cornish, Jean-Hugues Dalle, Maurizio Caniglia, Marco Zecca, Ayse Acma, Chantal Kenzey, Federica Giannotti, Christina Peters, Vanderson Rocha, Peter Bader, Eliane Gluckman, Annalisa Ruggeri
Journal: Blood (2014)
Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18
Authors: Harry Pick, Priya Daniel, Chamira Rodrigo, Thomas Bewick, Deborah Ashton, Hannah Lawrence, Vadsala Baskaran, Rochelle C Edwards-Pritchard, Carmen Sheppard, Seyi D Eletu, Samuel Rose, David Litt, Norman K Fry, Shamez Ladhani, Meera Chand, Caroline Trotter, Tricia M McKeever, Wei Shen Lim
Journal: Thorax (2019)

Background Changes over the last 5 years (2013–18) in the serotypes implicated in adult pneumococcal pneumonia and the patient groups associated with vaccine-type disease are largely unknown. Methods We conducted a population-based prospective cohort study of adults admitted to two large university hospitals with community-acquired pneumonia (CAP) between September 2013 and August 2018. Pneumococcal serotypes were identified using a novel 24-valent urinary monoclonal antibody assay and from blood cultures. Trends in incidence rates were compared against national invasive pneumococcal disease (IPD) data. Persons at risk of vaccine-type pneumonia (pneumococcal conjugate vaccine (PCV)13 and pneumococcal polysaccharide vaccine (PPV)23) were determined from multivariate analyses. Findings Of 2934 adults hospitalised with CAP, 1075 (36.6%) had pneumococcal pneumonia. The annual incidence of pneumococcal pneumonia increased from 32.2 to 48.2 per 100 000 population (2013–18), predominantly due to increases in PCV13non7-serotype and non-vaccine type (NVT)-serotype pneumonia (annual incidence rate ratio 1.12, 95% CI 1.04 to 1.21 and 1.19, 95% CI 1.10 to 1.28, respectively). Incidence trends were broadly similar to IPD data. PCV13non7 (56.9% serotype 3) and PPV23non13 (44.1% serotype 8) serotypes were identified in 349 (32.5%) and 431 (40.1%) patients with pneumococcal pneumonia, respectively. PCV13-serotype pneumonia (dominated by serotype 3) was more likely in patients in the UK pneumococcal vaccination clinical risk group (adjusted OR (aOR) 1.73, 95% CI 1.31 to 2.28) while PPV23-serotype pneumonia was more likely in patients outside the clinical risk group (aOR 1.54, 95% CI 1.13 to 2.10). Interpretation The incidence of pneumococcal CAP is increasing, predominantly due to NVT serotypes and serotype 3. PPV23-serotype pneumonia is more likely in adults outside currently identified clinical risk groups.
KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.
Authors: Kerstin M Kampa, Tanja Grandl, Sandra Mueller, Emmanuel Normant, Michael Walter, Wolfgang Schuetz, Lothar Kanz, Michael C Heinrich, Marcus M Schittenhelm
Journal: Blood (2009)
ROCK Trial (NCCH1709): Nivolumab monotherapy in Rare cancer patients with mismatch repair deficiency biomarker: phase II
Authors: Yosuke Amaya, Kan Yonemori, Hitomi Sumiyoshi Okuma, Shoko Narita, Akihiro Hirakawa, Natsuko Okita, Tamie Sukigara, Masashi Kanai, Manabu Muto, Kenichi Nakamura, Yasuhiro Fujiwara
Journal: Annals of Oncology (2019)
Transplantation of T-Cell Depleted Peripheral Blood Haematopoietic Stem Cells from an HLA-Disparate Family Donor for Children with Hematological Malignancies.
Authors: Franco Locatelli, Daniela Pende, Patrizia Comoli, Marco Zecca, Giovanna Giorgiani, Cesare Perotti, Maria Ester Bernardo, Laura Salvaneschi, Rita Maccario, Alessandro Moretta, Lorenzo Moretta
Journal: Blood (2007)
Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Authors: Deborah A. Thomas, Michael Rytting, Susan O'Brien, Stefan Faderl, William G. Wierda, Anna Franklin, Rebecca Garris, Farhad Ravandi, Jorge Cortes, Hagop M. Kantarjian
Journal: Blood (2009)
Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,
Authors: Jorge E. Cortes, Franck E. Nicolini, Meir Wetzler, Jeffrey H. Lipton, Luke P. Akard, Adam Craig, Nisha Nanda, Carrie Dial, Annie-Claude Benichou, Katie Cairati, Michele Baccarani, Gerard T. Kennealey, Hagop M. Kantarjian
Journal: Blood (2011)
Therapeutic Targeting of the Histone Ubiquitination-Methylation Axis in T Cell Leukemia
Authors: Panagiotis Ntziachristos, Kelly Arcipowski, Carlos Alberto Martinez, Yixing Zhu, Andrew G. Volk, Suresh Kumar, Paul M Thomas, Pieter Van Vlierberghe, Nobuko Hijiya, Stacy Marshall, Jack Wang, Jian Wu, Neil L Kelleher, John Crispino
Journal: Blood (2016)
Inhibition of Phosphotyrosine Phosphatase-1B (PTP1B) Induces Resistance to the ABL Kinase Inhibitor Imatinib Mesylate (Gleevec®) in BCR-ABL Positive Leukemic Cells.
Authors: Noriko Koyama, Steffen Koschmieder, Sandhya Tyagi, Silke Myloch, Heike Nuernberger, Tanja Rossmanith, Wolf Karsten Hofmann, Dieter Hoelzer, Oliver Gerhard Ottmann
Journal: Blood (2004)
Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
Authors: E.M. O’Reilly, J.F. Hechtman
Journal: Annals of Oncology (2019)

Although rare, NTRK gene fusions are known to be oncogenic drivers in pancreatic ductal adenocarcinoma (PDAC). We report the response of a metastatic CTRC-NTRK1 gene fusion-positive PDAC to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib and the eventual development of resistance to treatment.
IgM Myeloma: A Multicenter Retrospective Study of 159 Patients
Authors: Jorge J. Castillo, Artur J. Jurczyszyn, Edvan Crusoe, Jacek Czepiel, Julio Davila, Angela Dispenzieri, Marion Eveillard, Mark A Fiala, Irene M. Ghobrial, Alessandro Gozzetti, Joshua Gustine, Roman Hájek, Vânia Hungria, Jiri Jarkovsky, David Jayabalan, Jacob P. Laubach, Barbara Lewicka, Vladimir Maisnar, Elisabeth E. Manasanch, Philippe Moreau, Hareth Nahi, Ruben Niesvizky, Claudia E. Paba-Prada, Tomas Pika, Ludek Pour, John L Reagan, Paul G Richardson, Jatin J. Shah, Ivan Spicka, Ravi Vij, Anna Waszczuk, Morie A. Gertz
Journal: Blood (2016)
Deglycosylated Human Monoclonal Antibody Against HPA-1a Prevents Anti-HPA-1a Alloantibodies Mediated Endothelial Apoptosis
Authors: Hevi Wihadmadyatami, Monika Burg-Roederfeld, Silke Werth, Changgeng Ruan, Mingwang Wei, Gregor Bein, Ulrich J. Sachs, Sentot Santoso
Journal: Blood (2014)
Factor XII Promotes Leukocyte Inflammation and Its Deficiency Results in Faster Wound Healing
Authors: Evi Stavrou, Gretchen A. LaRusch, Matthew J. Fullana, Gary E. Wnek, Cheng-Kui Qu, Wen-Mei Yu, Howard J. Meyerson, Chao Fang, Nicholas P. Ziats, Alvin H. Schmaier
Journal: Blood (2011)